Earlybird VC

€10tn sits in German private capital. Almost none of it flows to long-term startup growth.

Investors still call venture too risky, too hard to regulate, and weaker than buyout. Earlybird & 23 other VCs published the data that busts all three myths.

Recap from the GVGF Forum 👇

Clinical trial data review is getting smarter.

Our portfolio company Rivia has launched Data Findings, an AI-powered module that automates data checks and helps clinical teams identify and resolve issues faster.

With Scancell as its first adopter, Rivia is accelerating clinical development. Congratulations to Erik Scalfaro and the entire Rivia team!

Read more details below.

From roundtables to a full-day Summit.

The first Gradient Descending Summit at Beaverbrook explored the questions shaping AI, from infrastructure and GTM to brand and pricing.

A first glimpse of the conversations below. Full film coming soon!

The first-ever Gradient Descending Summit has begun at Beaverbrook.

After a year of Gradient Descending roundtables, today expands the series into a deeper discussion on where AI is heading, and what it takes to build enduring companies as the technology continues to evolve.

@AndreRetterath, General Partner at Earlybird, opened the day by welcoming our guests and setting the scene for the conversations ahead, while also recognising the partners supporting this year’s Summit.

More from the Summit throughout the day.

Cc: @stripe, @NotionHQ, @deel, @HSBCInnovation

From AI agent security and AI-driven sales to industrial robotics and inference economics.

October's Gradient Descending sessions took us to Turin, Berlin, Zurich, and London to explore what it takes to make technology work at scale.

Our latest Perspectives recap: go.earlybird.com/zNYeuth8Wc